Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Multiple drugs

Multiple drugs Reactions 1704, p259 - 2 Jun 2018 Stem cell mobilization failure : case report A 14-year-old girl experienced stem cell mobilization failure following treatment with vincristine, ifosfamide, doxorubicin, etoposide, cyclophosphamide, temozolomide, irinotecan and bevacizumab [time to reaction onset not stated]. The girl, who was diagnosed with extraosseus stage I Ewing’s sarcoma in April 2009, started receiving treatment with IV vincristine 1.5 mg/m on day 1, IV ifosfamide 2 2 3,000 mg/m on days 1–3, IV doxorubicin 20 mg/m on days 1–3, IV etoposide 150 mg/m on days 1–3 (every three weeks x 6 cycles). She completed 6 cycles prior to surgical resection. In October 2009, she received 8 cycles of consolidation with vincristine IV 1.5 mg/m2 on day 1, IV actinomycin (unspecified) 0.75 mg/m on days 1–2 and IV cyclophosphamide 1,500 mg/m on day 1 (every three weeks x 8 cycles). In April 2010, she developed early relapse and a second chemotherapy line was given with 5 cycles of oral temozolomide 100 mg/m on days 1–21, IV irinotecan 20 mg/m on days 1–5 and 8–13 and IV bevacizumab 350 mg/m on day 1 (every 21 days x 5 cycles). In July 2010, a second surgical resection plus radiotherapy localized http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Multiple drugs

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Multiple drugs

Abstract

Reactions 1704, p259 - 2 Jun 2018 Stem cell mobilization failure : case report A 14-year-old girl experienced stem cell mobilization failure following treatment with vincristine, ifosfamide, doxorubicin, etoposide, cyclophosphamide, temozolomide, irinotecan and bevacizumab [time to reaction onset not stated]. The girl, who was diagnosed with extraosseus stage I Ewing’s sarcoma in April 2009, started receiving treatment with IV vincristine 1.5 mg/m on day 1, IV ifosfamide 2 2 3,000 mg/m...
Loading next page...
 
/lp/springer_journal/multiple-drugs-COo0eVZvA0

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46902-6
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p259 - 2 Jun 2018 Stem cell mobilization failure : case report A 14-year-old girl experienced stem cell mobilization failure following treatment with vincristine, ifosfamide, doxorubicin, etoposide, cyclophosphamide, temozolomide, irinotecan and bevacizumab [time to reaction onset not stated]. The girl, who was diagnosed with extraosseus stage I Ewing’s sarcoma in April 2009, started receiving treatment with IV vincristine 1.5 mg/m on day 1, IV ifosfamide 2 2 3,000 mg/m on days 1–3, IV doxorubicin 20 mg/m on days 1–3, IV etoposide 150 mg/m on days 1–3 (every three weeks x 6 cycles). She completed 6 cycles prior to surgical resection. In October 2009, she received 8 cycles of consolidation with vincristine IV 1.5 mg/m2 on day 1, IV actinomycin (unspecified) 0.75 mg/m on days 1–2 and IV cyclophosphamide 1,500 mg/m on day 1 (every three weeks x 8 cycles). In April 2010, she developed early relapse and a second chemotherapy line was given with 5 cycles of oral temozolomide 100 mg/m on days 1–21, IV irinotecan 20 mg/m on days 1–5 and 8–13 and IV bevacizumab 350 mg/m on day 1 (every 21 days x 5 cycles). In July 2010, a second surgical resection plus radiotherapy localized

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

There are no references for this article.